ProKidney Corp.
NASDAQ•PROK
CEO: Dr. Bruce Culleton M.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-06-30
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Contact Information
2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, NC, 27103, United States
336-999-7028
Market Cap
$908.95M
P/E (TTM)
-5.5
vs Industry 16.8
Dividend Yield (TTM)
--
52W High
$7.13
52W Low
$0.46
52W Range
2.3
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2024
Financial Dashboard
Q2 2025 Data
Revenue
$221.00K+0.00%
4-Quarter Trend
EPS
-$0.13-18.75%
4-Quarter Trend
FCF
-$60.62M+55.72%
4-Quarter Trend
Earnings Highlights
Key Highlights
No Data Available
Risk Factors
No Data Available
Outlook
No Data Available
Peer Comparison
Revenue (TTM)
MRVI
XNCR
ANABGross Margin (Latest Quarter)
PROK
KURAANABKey Metrics
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
N/M
Revenue Volatile
4-Quarter Net Income CAGR
N/M
Profitability Shift Observed
Cash Flow Stability
0%
Cash Flow Requires Attention
Research & Insights
Reports
All Years